AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $AVRO–AVROBIO, Inc. (NASDAQ: AVRO) (the ?Company?) today announced that the first patient has been dosed in the Company?s AVR-RD-04 investigational gene therapy program for cystinosis, a devastating lysosomal storage disease, in an ongoing Phase 1/2 clinical trial sponsored by academic collaborators at the University of California San Diego. The gene therapy is derived from the patient?s own hematopoietic stem cells, which are genetically modified to produce functio